Specialties

Reduced biopsy rate and improved malignancy rate with high-end imaging tool

Presented By

Dr Jordan Phillipps, Washington University School of Medicine, MO, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:24

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By

Elle Kim, John Hopkins University, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:19

Clinical patterns and outcomes in hypopigmented mycosis fungoides

Presented By

Dr Jong Bin Park, Kosin University, South Korea

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:10

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Prof. Laurie Sehn, University of British Columbia, Canada

Trial

Phase 3, inMIND

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:34

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Presented By

Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA; Dr Sameh Gaballa, Lee Moffitt Cancer Center, FL, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:31

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

Presented By

Dr Catherine Diefenbach, NYU Langone Health, NY, USA

Trial

Phase 1, BO42203

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:29

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands

Trial

Phase 1/2, ATALANTA-1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:27

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:25

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:23

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Presented By

Prof. Mark Levis, Johns Hopkins University, MD, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:20

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Presented By

Dr Ghayas Issa, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2, SAVE

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:17

Venetoclax plus azacitidine in young patients with AML

Presented By

Dr Daniel Pollyea, University of Colorado, CO, USA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:14

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

Presented By

Dr Jennifer Marvin-Peek, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:12

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

Presented By

Dr Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:09

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Presented By

Dr Ioannis Mantzaris, Montefiore Medical Center, NY, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:07

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Prof. Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:05

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:03

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:57

KCRd offers overall survival benefit over CRd in newly diagnosed MM

Presented By

Dr Charlotte Pawlyn, Institute of Cancer Research, UK

Trial

Phase 3, Myeloma XI/XI+

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:53

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:49

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

Trial

Phase 1/2, CA057-003

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:47

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

Trial

Phase 3, IFM2017-03

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:44

CEPHEUS: Further support for daratumumab regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, CEPHEUS

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:42

Margetuximab does not improve pCR rate in HER2-positive early breast cancer

Presented By

Dr Adrienne Waks, Dana-Farber Cancer Institute, USA

Trial

Phase 2, MARGOT/TBCRC052

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:37

Obesity is associated with worse prognosis in early-stage breast cancer

Presented By

Dr Hongchao Pan, University of Oxford, UK

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:35

T-DXd outperforms T-DM1 regardless of baseline genomic alterations in HER2-positive metastatic breast cancer

Presented By

Dr Paolo Tarantino, Dana-Farber Cancer Institute, USA

Trial

Phase 3, DESTINY-Breast03

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:33

Immediate surgery can offer long-term benefits for elderly patients with early-stage breast cancer

Presented By

Prof. Robert Hills, University of Oxford, UK

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:33

Long-term benefit of olaparib seen in high-risk early BRCA1/2-mutated breast cancer

Presented By

Prof. Judy Garber, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, OlympiA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:31

Encouraging results of neoadjuvant SHR-A1811 in the treatment of HER2-positive breast cancer

Presented By

Dr Junjie Li, Fudan University Cancer Hospital, China

Trial

Phase 2, FASCINATE-N

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:30

Active monitoring is a viable option for patients with low-risk DCIS

Presented By

Prof. Eun-sil Hwang, Duke University School of Medicine, NC, USA

Trial

COMET

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:28

Additional CDK4/6 inhibition in HER2-positive patients achieves clinically meaningful outcomes

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, USA

Trial

Phase 3, AFT-38 PATINA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:23

NATALEE: Success with adjuvant ribociclib leads to FDA approval in early breast cancer

Presented By

Dr Jennifer Gao, CDER, U.S. Food and Drug Administration, USA

Trial

Phase 3, NATALEE

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 12:00

Inavolisib: The first FDA-approved treatment for use in a triple combination for metastatic breast cancer

Presented By

Dr Suparna Wedam, CDER, U.S. Food and Drug Administration, USA

Trial

Phase 3, INAVO120

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:58

Imlunestrant monotherapy improves PFS in ESR1-mutated patients, not in the overall population

Presented By

Dr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, EMBER-3

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:54

Neoadjuvant niraparib plus dostarlimab shows pCR benefit in BRCA-mutated, ER-positive/HER2-negative breast cancer 

Presented By

Dr Erica Mayer, Dana-Farber Cancer Institute, USA

Trial

Phase 2, TBCRC 056

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:50

Neoadjuvant HER3-DXd achieves pCR and ORR results similar to multi-agent chemotherapy

Presented By

Dr Mafalda Oliveira, University Hospital Vall d’Hebron, Spain

Trial

Phase 2, SOLTI VALENTINE

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:46

SONIA: Potential to defer CDK4/6 inhibitor treatment without impacting HRQoL

Presented By

Prof. Kari Wisinski, University of Wisconsin, USA

Trial

Phase 3, SONIA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:43

Improved TTF and PFS seen with palbociclib plus ET in real-world PADMA study

Presented By

Prof. Sibylle Loibl, University of Frankfurt, Germany

Trial

Phase 4, PADMA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:39

KEYNOTE-522 finds prognostic value of TMB and gene profiles in TNBC

Presented By

Dr Joyce O’Shaughnessy, Baylor University Medical Center, USA

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:36

The ZEST trial sheds light on the use of ctDNA to predict breast cancer recurrence

Presented By

Prof. Nicholas Turner, Royal Marsden Hospital, UK

Trial

Phase 3, ZEST

Conference

SABCS 2025

Type

Peer-reviewed article

23 January 2025 11:00

No added EFS benefit with neoadjuvant atezolizumab in TNBC

Presented By

Prof. Charles Geyer, University of Pittsburgh, USA

Trial

Phase 3, NSABP B-59/GBG-96-GeparDouze

Conference

SABS 2024

Type

Peer-reviewed article

23 January 2025 10:22

No OS benefit at 10 years with post-mastectomy RT in intermediate-risk breast cancer

Presented By

Prof. Ian Kunkler, University of Edinburgh, Scotland

Trial

Phase 3, SUPREMO

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 10:18

Single-modality radiotherapy may better preserve HRQoL than ET in elderly patients

Presented By

Dr Icro Meattini, University of Florence, Italy

Trial

Phase 3, EUROPA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 10:11

Tamoxifen reduces ipsilateral breast recurrence in “good risk” DCIS patients without RT

Presented By

Dr Jean Wright, Johns Hopkins Medicine, USA

Trial

NRG/RTOG 9804, ECOG-ACRIN E5194

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 10:09

Meet the Trialist: Prof. Hope Rugo on the P-VERIFY results

Expert

Prof. Hope Rugo, UC San Francisco, CA, USA

Trial

P-VERIFY

Conference

SABCS 2024

21 January 2025 12:50

Meet the Trialist: Prof. Mats Jerkeman on the ALTAMIRA trial

Expert

Prof. Mats Jerkeman, Skane University Hospital and Lund University, Sweden

Trial

Phase 2, ALTAMIRA

Conference

ASH 2024

23 December 2024 15:15

Meet the Expert: Prof C. Ola Landgren discusses the value of real-world evidence

Expert

Prof. C. Ola Landgren, Sylvester Comprehensive Cancer Center, University of Miami, FL, USA

Conference

ASH 2024

23 December 2024 15:07

TACITO: Does faecal microbiota transplantation improve survival in mRCC?

Presented By

Dr Gianluca Ianiro, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:19

Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

Presented By

Dr Maria Mannino, Catholic University of the Sacred Heart, Italy

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:02

Trastuzumab deruxtecan also effective in patients with brain metastases

Presented By

Dr Nancy Lin, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, DESTINY-Breast12

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:37

High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC

Presented By

Dr Iris Nederlof, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, BELLINI

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:35

Local HER2 IHC0 is often HER2-low or -ultralow

Presented By

Prof. Giuseppe Viale, University of Milan, Italy

Trial

Phase 3, DESTINY-Breast06

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:32

First-line capivasertib improves PFS but not OS in metastatic TNBC

Presented By

Prof. Heather McArthur, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, CAPItello-290

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:27

Breastfeeding does not increase the risk of breast cancer recurrence

Presented By

Dr Fedro Peccatori, European Institute of Oncology, Italy; Dr Eva Blondeaux, University of Genova, Italy

Trial

POSITIVE, BRCA BCY Collaboration

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:23

More highlights in Breast Cancer

Trial

HERA, NATALEE, KEYNOTE-522, HypoG-01

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:20

Adjuvant durvalumab does not improve survival in completely resected NSCLC

Presented By

Prof. Glenwood Goss, Ottawa Hospital, Canada

Trial

Phase 3, BR.31

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:15

NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, ALKOVE-1

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:13

Relatlimab addition benefits only a subgroup of metastatic NSCLC

Presented By

Prof. Nicolas Girard, Institut Curie, France

Trial

Phase 2, RELATIVITY-104

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:11

More highlights in Lung Cancer

Trial

Phase 3, MARIPOSA, MARIPOSA-2

Type

Peer-reviewed article

4 November 2024 12:08

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC

Presented By

Prof. Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, TiNivo-2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:52

Faecal transplants show promise in enhancing metastatic RCC treatment

Presented By

Dr Chiara Ciccarese, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:44

More highlights in Renal Cell Carcinoma

Trial

LITESPARK-005, SUNNIFORECAST

Type

Peer-reviewed article

4 November 2024 11:42

Reclassification of AML Subtypes and Risk in Light of ICC and ELN2022

17 September 2024 13:51

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:08

SPOTLIGHT on new targets in immunotherapy: claudin 18.2

Presented By

Prof. Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:03

AI facilitates early detection of hepatocellular carcinoma

Presented By

Dr Kin Nam Kwok, Hong Kong University, Hong Kong

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:59

Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer

Presented By

Dr Jia Liu, St Vincent’s Hospital Sydney, Australia

Trial

Phase 1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:58

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:53

New analyses validate TAP and CPS scores for PD-L1 expression

Presented By

Prof. Markus Moehler; Prof. Eric Raymond

Trial

Phase 3, RATIONALE-305; RATIONALE-306

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:30

MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, UK

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:09

The landscape of TP53 mutations and their prognostic impact in CLL

Presented By

Dr Consuelo Bertossi, University Hospital Ulm, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 15:11

Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis

Presented By

Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL

Presented By

Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain

Trial

Phase 3, PhALLCON

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Prof. Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, TUD-APOLLO-064

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Excellent phase 3 results for asciminib in chronic myeloid leukaemia

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:24

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Post-intensification data confirm superiority of quadruple therapy in MM

Presented By

Prof. Marc Raab, University Hospital Heidelberg, Germany

Trial

Phase 3, GMMG-HD7

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Promising phase 1 results for novel CAR T-cell therapy in MM

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:16

Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients

Expert

Samantha Nier, Acute Leukemia Advocates Network

1 August 2024 14:16

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By

Dr Elske Gootjes, Radboudumc, the Netherlands

Trial

Phase 3, ORCHESTRA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:53

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 8HW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:44